BioGaia Signs New Exclusive Agreement in the UK
STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
BioGaia (STO:BIOG-B) has today extended its global contract with Nestle Nutrition by signing an agreement with the company’s UK infant nutrition business for the exclusive rights to sell BioGaia’s ProTectis Baby Drops in the United Kingdom and Ireland.
Launch is planned to take place in the beginning of 2015.
Nestle Nutrition UK will market both BioGaia ProTectis Baby Drops, which is BioGaia's biggest product, and BioGaia ProTectis Baby Drops with vitamin D. Both products contain BioGaia's patented and well-documented probiotic strain Lactobacillus reuteri Protectis. Today the drops are sold in 60 countries worldwide.
“I am delighted that we after many years of preparations have been able to conclude a contract for this large market. We have established an important key opinion leader network in the UK and the drops are already sold in a few hospital pharmacies. Considering Nestle Nutrition’s presence in the market and our preparatory work I am convinced that sales will expand quickly”, says Peter Rothschild, President, BioGaia.
Latest press releases from BioGaia
2014-06-17 BioGaia signs distribution agreement for India
2014-05-07 Annual General Meeting of BioGaia AB
2014-05-06 BioGaia AB: Interim management statement 1 January-31 March 2014
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 18 June 2014, 1:15 pm CET.
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
This information was brought to you by Cision http://news.cision.com